Gapping down
In reaction to disappointing earnings/guidance:
- FNSR -0.5%
M&A news:
- GSK -6.8% (To acquire TSRO for $75/share); to divest Horlicks and other Consumer Healthcare nutrition products to Unilever (UN, UL); total consideration valued at approximately £3.1 billion)
Other news:
- BLUE -8% (clinical studies of LentiGlobin Gene Therapy)
- CFRX -4.3% (files for $100 mln mixed shelf offering)
- AUPH -3.5% (entered into $30 mln open market sale agreement with Jefferies)
- KIRK -2.4% (pulling back following last week's strength)
Analyst comments:
- VZ -0.5% (downgraded to Neutral from Overweight at JP Morgan)
